Home › BOSTON SCIENTIFIC CORPORATION › Jagtome RX 39
Jagtome RX 39
BOSTON SCIENTIFIC CORPORATION · Model M00573080 · UDI-DI 08714729776642
KNS
Prescription
10
510(k) clearances
17,379
Adverse events (81 deaths)
121
Recalls
118
Facilities
Description
Sphincterotome
Recalls
| Date | Firm | Reason |
|---|---|---|
| 2026-01-07 | Olympus Corporation of the Americas | Devices which did not undergo thermoforming could deform and lose performance. |
| 2026-01-07 | Olympus Corporation of the Americas | Devices which did not undergo thermoforming could deform and lose performance. |
| 2026-01-07 | Olympus Corporation of the Americas | Devices which did not undergo thermoforming could deform and lose performance. |
| 2026-01-07 | Olympus Corporation of the Americas | Devices which did not undergo thermoforming could deform and lose performance. |
| 2026-01-07 | Olympus Corporation of the Americas | Devices which did not undergo thermoforming could deform and lose performance. |
| 2026-01-07 | Olympus Corporation of the Americas | Devices which did not undergo thermoforming could deform and lose performance. |
| 2026-01-07 | Olympus Corporation of the Americas | Devices which did not undergo thermoforming could deform and lose performance. |
| 2026-01-07 | Olympus Corporation of the Americas | Devices which did not undergo thermoforming could deform and lose performance. |
| 2026-01-07 | Olympus Corporation of the Americas | Devices which did not undergo thermoforming could deform and lose performance. |
| 2026-01-07 | Olympus Corporation of the Americas | Devices which did not undergo thermoforming could deform and lose performance. |
Query this across every FDA database — by API.
Linked GUDID · 510(k)/PMA · MAUDE · recalls · establishments. Free tier, no card required.
Get your free API keyRead the docsData compiled from public U.S. FDA sources (GUDID, 510(k)/PMA, MAUDE, recalls, establishment registration). Adverse-event reports are unverified and do not establish causation. Informational only — not medical, clinical, or regulatory advice.
